International Journal of Modern Engineering and Management

Polymeric Nanoparticle-Based Drug Delivery Systems for Enhanced Anticancer Efficacy: Synthesis, Characterisation, and In Vitro Evaluation of PLGA and Chitosan Nanocarriers Loaded with Curcumin

Author(s):

Madhuri Tripathi, Vinod Kumar Yadav

Affiliation:

Page No: 43-48-

Volume issue & Publishing Year: Volume 3, Issue 5, 2026/05/12

Journal: International Journal of Modern Engineering and Management | IJMEM

ISSN NO: 3048-8230

DOI: https://doi.org/10.5281/zenodo.20426574

Download PDF Cite this article

Abstract:

Curcumin, the principal bioactive polyphenol of Curcuma longa, exhibits potent anticancer activity through simultaneous modulation of multiple oncogenic signalling pathways including NF-κB, Nrf2, mTOR, and Wnt/β-catenin. However, curcumin's clinical translation is severely impaired by its extremely poor aqueous solubility (11 ng/mL at pH 7.0), rapid metabolic inactivation, and low oral bioavailability (< 1%). Polymeric nanoparticle encapsulation represents a promising strategy to overcome these biopharmaceutical limitations by protecting curcumin from premature degradation, enabling sustained release at the tumour site via enhanced permeability and retention (EPR) effect, and facilitating cellular uptake through endocytic pathways. This study systematically synthesises and characterises curcumin-loaded nanoparticles using two distinct polymer matrices — poly(lactic-co-glycolic acid) (PLGA) via nanoprecipitation and chitosan via ionic gelation — and comprehensively evaluates their physicochemical properties, drug release kinetics, and anticancer efficacy against MCF-7 (breast cancer) and A549 (lung cancer) cell lines. PLGA-curcumin nanoparticles (PLGA-Cur-NP) exhibited particle size of 182±14 nm, zeta potential of −28.4±2.1 mV, and encapsulation efficiency of 88.3%, with sustained biphasic release of 91.2% drug over 72 hours. Chitosan-curcumin nanoparticles (CS-Cur-NP) showed particle size of 216±18 nm, zeta potential of +16.8±1.4 mV, and encapsulation efficiency of 82.7%, exhibiting pH-responsive drug release with accelerated release at pH 5.5 (tumour microenvironment). MTT assay demonstrated that PLGA-Cur-NP achieved IC₅₀ of 12.4 µg/mL against MCF-7, representing a 4.8-fold improvement over free curcumin (IC₅₀ = 59.7 µg/mL).

Keywords:

curcumin, PLGA nanoparticles, chitosan nanoparticles, drug delivery, anticancer, encapsulation efficiency, drug release kinetics, MCF-7, A549, EPR effect, nanomedicine, bioavailability

Reference:

• [1] Anand, P., Nair, H. B., Sung, B., Kunnumakkara, A. B., Yadav, V. R., Tekmal, R. R., & Aggarwal, B. B. (2010). Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioavailability in vitro and in vivo. Biochemical Pharmacology, 79(3), 330-338.

• [2] Correa, E., Morales, A., Gallego, M., Orive, G., & Hernandez, R. M. (2020). Chitosan nanoparticles for the controlled delivery of drugs and peptides. Drug Delivery and Translational Research, 10(4), 1027-1043.

• [3] Dubey, P. R., & Srivastava, A. K. (2022). Curcumin nanoformulations: Current status and prospects in cancer therapy. Journal of Drug Delivery Science and Technology, 68, 103091.

• [4] Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy. Cancer Research, 46(12), 6387-6392.

• [5] Mitra, S., Gaur, U., Ghosh, P. C., & Maitra, A. N. (2001). Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. Journal of Controlled Release, 74(1-3), 317-323.

• [6] Parveen, S., & Sahoo, S. K. (2011). Biodegradable nanoparticles loaded with doxorubicin for cancer therapy. Journal of Drug Targeting, 19(5), 362-378.

• [7] Sarika, P. R., & Nirmala, R. J. (2016). Curcumin loaded gum arabic aldehyde-gelatin nanogels for breast cancer therapy. Materials Science and Engineering: C, 65, 331-337.

• [8] Srivastava, A. K., Tripathi, M., & Yadav, V. K. (2023). Optimisation of PLGA nanoparticle formulation variables for enhanced curcumin loading efficiency. Asian Journal of Pharmaceutics, 17(1), 45-54.

• [9] Yallapu, M. M., Jaggi, M., & Chauhan, S. C. (2012). Curcumin nanoformulations: A future nanomedicine for cancer. Drug Discovery Today, 17(1-2), 71-80.

• [10] Aggarwal, B. B., & Sung, B. (2009). Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends in Pharmacological Sciences, 30(2), 85-94.

• [11] Yadav, V. K., & Kumar, S. (2021). Nanoparticle surface engineering strategies for improved cellular uptake and bioavailability. Nanomedicine: Nanotechnology, Biology and Medicine, 31, 102320.

• [12] Tripathi, M., Garg, A., & Singh, R. (2022). In vitro cytotoxicity evaluation of polymeric nanoparticles against human cancer cell lines: A comparative analysis. International Journal of Nanomedicine, 17, 4119-4134.